Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT03053440 |
Date of registration:
|
07/02/2017 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
ASPEN |
Scientific title:
|
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) |
Date of first enrolment:
|
January 25, 2017 |
Target sample size:
|
229 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03053440 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Australia
|
Belgium
|
Czechia
|
France
|
Germany
|
Greece
|
Italy
|
Netherlands
|
Poland
|
Spain
|
Sweden
|
United Kingdom
|
United States
| | | |
Contacts
|
Name:
|
Aileen Cohen, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
BeiGene |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|